










Plasma Interleukin-6 concentration in patients
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Abstracts: Recent studies have indicated the potential role of the immune system in the patho-
physiology and progression of congestive heart failure(CHF). Interleukin-6(IL6) level has been
reported to be increased in patients with CHF. In this study, we evaluated whether IL-6 is
produced in the peripheral circulation in patients with CHF, and determined the relationships
between the plasma levels of IL6 and other neurohumoral factors.
A comparison was made of the plasma levels Iし6 between the femoral artery and the femoral
vein in 13 normal subjects and in 80 patients with CHF. In these subjects, we also measured
hemodynamic parameters as well as other neurohumoral factors such as norepinephrine, epine-
phrine. Plasma IL-6 levels were higher in patients with CHF than in normal subjects. Moreover,
in both normal subjects and CHF patients, plasma levels of IL6 in the femoral vein(FV) were
higher than those in the femoral artery(FA) (FA vs. FV in normal; 1.0 vs. 1.15, mild CHF; 2.48
vs. 2.9, severe CHF; 12.26 vs. U.lpg/ml). Plasmaル6 level was correlated with norepine-
phrine (r -0.838, p<0.0001) and epinephrine (r -0.635, p<0.0001). There was a negative corre-
lation between IL6 level and left ventricular ejection fraction (r --0.323, p<0.005). Moreover,
arteriovenous IL-6 spillover in the leg increased with the severity of CHF(normal; 0.43, mild
CHF; 0.92, severe CHF; 10.1 ng/min) and was also correlated with plasma catecholamines.
These results indicate that plasma IL-6 is produced in the peripheral vascular bed and increases
with the seventy of CHF and that the increase of plasma IL-6 is mainly associated with the
activation of the sympathetic nervous system in patients with CHF, suggesting an important role
of IL6 in the pathophysiolosy of CHF.
Key wo「as: Interleukin(IL)-6, Congestive heart failure(CHF), Peripheral circulation, 〟-blocker
therapy, Norepinephrine


























































近IL6 ・ IL6 receptor transgenic mouseで心筋細
胞が肥大することが明らかになり9UL6の心筋細胞
への直接の影響についても示唆された.さらに, IL



































































IL6 spillover- (IL-6 inFV-IL6 inFA)× (1 -
Ht/100) × CO(ng/mm;
Interleukin-6の測定はELISA法によりQuanti-




















TNFαは同じくQuantikine HS TNF assay Kit
(R&D System)を用い高感度ELISA法により行
sia
Atrial natriuretic peptide (以下ANPと略す) ,
Brain natriuretic peptide (以下BNPと略す),














討した.解析方法は, stepwise multiple regression
法にておこなった.解析する21項目の内容は,神経
体液性因子として　ANP, BNP, ET-1, norepine-





































2.58±0.23 vs. 2.90±0.27pg/ml, p<0.01,重症心














ANP濃度, BNP濃度, ET-1濃度, norepinephrine












Normal mild CHF severe CHF
図1正常群(normal),軽症心不全群(mildCHF),重症心不全群　severeCHF),す
べてにおいて大腿静脈血中(FV)のIL6濃度(異)は大腿動脈血中(FA)のIL-6浪度(白)










Normal mild CHF severe CHF
図2 IL6の宋柑循環での産生畳(IL-6 spilレ
over-IL-6 concentlation (FV-FA) ×


































年 齢 (year) 0.184 n.s. n.s. 0.121 n.s. n.s.
Body M assIndex (kg/ irf) 【0.227 < 0.05 n.s. -0.183 n.s. n.s.
治 療 薬
利 尿 剤 一0.04 n.s. n.s. -0.03 n.s. n.s.
ジ ギ タ リス 製 剤 0.14 n.s. n.s. 0. n.s. n.s.
ACE 阻 害 薬 -0.125 n.s. n.s. -0.09 n.s. n.s.
血 管 拡 張 薬 -0.2 n.s. n.s. -0.163 n.s. n.s.
β 遮 断 薬 一0.08 n.s. <0.05 0ー.06 n.s. n.s.
血 行 動 態
心 拍 数 (/ 分 ) 0.343 <0.005 n.s. 0.256 <0.05 n.s.
平 均 血 圧 (mmH e) 】0.09 n.s. n.s. 0.14 n一S. n.s.
右 房 圧 (mmHg) 0.325 n.s. n.s. 0.261 n.s. n.s.
肺 動 脈 模 入 圧 (mmHg) 0、295 く0.0001 n.s. 0.262 < 0.05 n.s.
平 均 肺 動 脈 圧 (mmHg) 0.231 n.s. n.s. 0.252 n.s. n.s.
心 抽 出 量 (1/ 分 ) 0.091 n.s. n.s. 0.134 n.s. n.s.
駆 出 率 (% ) 0ー.323 <0.005 n.s. -0.242 < 0.05 n.s.
神 経 体 液 性 因 子
ANP 0.258 <0.05 n.s. 0.494 <0.0001 < 0.01
BN P 0.3 <0.01 n.s. 0.399 <0.001 n.s.
angiotensin II 0.375 <0.001 n.s. 0.337 <0.005 n.s.
ET-1 0.536 <0.0001 n.s. 0.557 <0.0001 n.s.
TN Fα 0.386 <0.001 n.s. 0.515 <0.0001 n.s.
epinephrine 0、635 <0.0001 <0.0001 0.346 <0.005 n.s.
norepinephnne 0、838 < 0.0001 <0.0001 0.875 <0.0001 < 0.0001
表2　ドーパミン点滴による血費IL-6濃度の変化
患者 性別 疾 患
plasmaIL一6(pg/ml) plasmaIL-6(pg/ml) plasmaIL~6
増 加率 (%)ドーパ ミン点滴 前 ドーパ ミン点 滴後
K.T. 男性 僧 帽 弁 閉 鎖 不 全 症 6.09 9.89 38.6
K.S. 女性 拡 張 型 心 筋 症 5. 9.41 65.6
K.O. 男性 拡 張 型 心 筋 症 4.19 14.66 249.9






































PCWP (mmHg)　　　　　　　　Ejection Fraction (%)
図3 (左上) norepinephrineは血襲IL-6と強い正の相関を示した(r-0.838, P<
0.0001) (右上)epinephrineは血梁IL6と強い正の相関を示した. ( r -0.635, P <0.0001)
(左下)肺動脈模入圧(PCWP)は血祭IL-6と正の相関を示した( r -0.295, P <0.0001)












治療前 (n=9) 治療後(n= 9) P Value
Plasm a IL 6(pg/ ml) 4.29±0.82 2.15± 0.35 < 0.05
NY HA 2.8±0.2 2± 0.1 < 0.05
心 拍 数 (/ 分 ) 85.8± 5.1 80.6± 5.15 n.s.
平 均 血 圧 (mmHg) 92.2± 5.1 .1±4.6 < 0.05
宜F(% ) 34.6± 3.8 44.5±3.4 < 0.05
ANP(pg/ ml) 136.1± 26.6 77.6± 18.4 < 0.05
BNP(pg/ ml) 327.4± 90.8 223.3±83.8 < 0.05
Epiriephrine(pg/ ml) 42.0± 7.8 28.6± 7.1 n.s.
N orepinephrine(pg/ ml) 637.1± 129 394.9± 54.9 < 0.05
が,心臓肥大促進物質やあるcardiotropin-1のrece-
ptor構造と一部同じであると言う報告2,4,21,24)や,ヒ































































































































1 ) Bellido T, Stahl N, Farruggella TJ, Borba V,
Yancopoulos GD, Manolagas SC: Detection
of receptors for interleukin-6, interleukin-
11 , leukemia inhibitory factor, oncostatin M,
and ciliary neurotrophic factor in bone mar-
row stromal/osteoblastic cells. J Clin Invest
97: 431-437, 1996.
2) Benigni F, Fantuzzi G, Sacco S, Sironi M,
Pozzi P, Dinarello CA, Sipe JD, Poli V,
Cappelletti M, Paonessa G, Pennica D,
Panayotatos N, Ghezzi P: Six different cyto-
kines that share GP130 as a receptor subunit,
induce serum amyloid A and potentiate the
-25-
久　永　智　子
induction of interleukin-6 and the activation
of the hypothalamus-pituitary-adrenal axis
by interleukin-1. Blood 87(5): 1851-1854,
1996.
3 ) Biasucci LM, Vitelli A, Liuzzo G, Altamura
S, Caligiuri G, Monaco C, Rebuzzi AG,
Ciliberto G, Maseri A: Elevated levels of
interleukin-6 in unstable angina. Circulation
94: 874-877, 1996.
4 ) Chevalier S, Fourcin M, Robledo 0, Wijdenes
J, Pouplard BA, Gascan H:Interleukin-6 fam-
ily of cytokines induced activation of differ-
ent functional sites expressed by gpl30 trans-
ducing protein. J Biol Chem 271 :14764-72,
1996.
5 ) Colucci WS, Packer M, Bristow MR, Girbert
M, Cohn JN, Fowler MB, Krueger SK, Hersh-
berger R, Uretsky BF, Bowers JA, Sackner-
Bernstein JD, Young ST, Holcslaw TL,
Lukas MA, (for the US Carvedilol Heart
Failure Study Group): Carvedilol inhibits clin-
ical progression in patients with mild symp-
toms of heart failure. Circulation 94: 2800-
2806, 1996.
6 ) Dutka D P, Elborn J S, Delamere F, Shale DJ,
Morris GK: Tumor necrosis factor alpha in
severe congestive cardiac failure. Br Hearり.
70: 141-143, 1993.
7 ) Finkel MS, OddisCV, Jacob TD, Watkins SC,
Hattler BG, Simmons RL: Negative inotropic
effects of cytokines on the heart mediated by
nitric oxide. Science 257: 387-389, 1992.
8) Gordon J, MacLean LD: A lymphocyte-
stimulating factor produced in vitro. Nature
208: 795-796, 1965.
9 ) Hirota H, Yoshida K, Kishimoto T, Taga T:
Continuous activation of gp130, a signaレ
transducing receptor component for interleu-
kin 6てelated cytokines, causes myocardial
hypertrophy in mice. Proc Natl Acad Sci U S
A 92: 4862-4866, 1995.
10) Kasakura S, Lowenstein L∴ A factor stimu-
latins UNA synthesis derived from the
medium of leucocyte cultures. Nature 208:
794 795, 1965.
ll) Katz SD, Rao R, Berman JW, Schwarz M,
Demopoulos L, Bijou R, Lejemtel TH: Patho-
physi logical co relates of increased serum
tumor necrosis factor in patients with conges-
tive heart failure. Relation to nitric oxide-
dependent vasodilation in the forearm circu・
lation. Circulation 90: 12-18, 1994.
12) K lly RA, Smith TV: Cytokines and cardiac
contractile function [editorial]. Circulation
95(4): 778-781, 1997.
13) Kishimoto T, Taga T, Yamasaki K, Matsuda
T, Tang B, Muraguchi A, Horii Y, Suematsu
S, Hirata Y, Yawata H, Shimizu M, Kawano
M, Hirano T: No mal and abnormal regula一
tion of human B cell differentiation by a new
cytokine, BSF2/IL6. Adv Exp Med Bio1
254: 135-143, 1989.
14) Kishimoto T,: The Biology of Interleukin-6.
Blood 74:ト10 , 1989.
15) Levine B, Kalman J, Mayer L, Fillit HM,
Packer M: Elevated circulating levels of
tumor necrosis factor in severe chronic heart
failure. N Engl  Med 323: 236-241, 1990.
16) Limas CJ, Goldenberg IF, Limas C. :Soluble
nterleukin-2 receptor levels in patients with
dilated cardiomyopathy. Correlation with
disease severity and cardiac autoantibodies
[see comments]. Circulation 91: 631-634,
1996.
17) Odeh M: Tumor necrosis factor-α as a
myocardial depressant substance. Int J Car-
d ol 42: 231-238, 1993.
18) Ohkawa F, Ikeda U, Kanbe T, Kawasaki K,
Shimada K∴ Effects of inflammatory cyt0-
kines on vascular tone. Cardiovasc Res 30:
711-715, 1995.
19) Packer M, Colucci WS, Sackner-Bernstein
JD, Li ng C, Goldscher DA, Freeman I, Kukin
ML, Kinhal V, Udelson JE, Klapholz M,
Gottlieb SS, Pearle D, Cody RJ, Gregory JJ,
Kantrowitz NE, Lejemtel TH, Young ST,
-26-
表題・慢性心不全患者にま‖ナる血祭インターロイキンー6濃度測定の意義とその上昇を規定する因子についての検討
Lukas MA, Shusterman NH,(for the PRE-
CISE Study Group): Double-blind, placebo-
controlled study of the effects of carvedilol in
patients with moderate to severe heart fail-
ure.The PRECISE trial. Circulation 94: 2793
-2799, 1996.
20) Pennica D, Shaw KJ, Swanson TA, Moore
MW, Shelton DL, Zioncheck KA, Rosenthal
A, Taga T, Paoni NF, Wool WI:
Cardiotrophin-1 Biological activities and
binding to the leukemia inhibitory factor
receptor/gpl30 signaling complex. J Biol
Chem 270: 10915-10922, 1995.
21) Robledo 0, Fourcin M, Chevalier S, Guillet C,
Auguste P, Pouplard-Barthelaix A, Pennica
D, Gascan H: Signaling of the cardiotropin-1
receptor. Evidence for a third receptor com-
ponenりBiol Chem 272: 4855-4863, 1997.
22) Shioi T, Matsumori A, Sasayama S.: Persist-
ent Expression of Cytokine in Chronic Stage
of Viral Myocarditis in Mice. Circulation 94:
2930-2937, 1996.
23) Smith TW, Balligand JL, Kaye DM, Wiviott
SD, Simmons WW, Han X, Michel T, Singh
K, Kelly RA: The role of the NO pathway m
the control of cardiac function. J Card Fail 2:
141-148, 1996.
24) Taga T.: Gpl30, a shared signal transducing
receptor component for hematopoietic and
neuropoietic cytokines. J Neurochem 67 :1-
10, 1996.
25) Torre-Amione G, Kapadia S, Benedict C,
Oral H, Young JB, Mann DL: Proinfram一
matory cytokine levels in patients with
depressed left ventricular ejection fraction: a
report from the Studies of Left Ventncurar
Dysfunction(SOLVD). J Am Coll Cardi01 27:
1201-1206, 1996.
26) Tsujinaka T, Fujita J, Ebisui C, Yano M,
Kominami E, Suzuki K, Tanaka K, Katsume
A, Ohsugi Y, Shiozaki H, Monden M: Inter-
leukin 6 receptor antibody inhibits muscle
atrophy and modulates proteolytic systems in
interleukin 6 transgenic mice. J Clin Invest
97: 244-254, 1996.
27) Tsutamot  T, Kanamori T, Morigami N,
Sugimoto Y, Yamaoka 0, Kinoshita M: Possi-
bility of downregulation of atnal natnuretic
peptide receptor coupled to guanylate cyclase
in peripheral vascular beds of patients with
chronic severe heart failure. Circulation 87:
70-75, 1993.
28) Tsutamoto T, Wada A, Maeda Y, Adachi T,
Kinoshita M: Relation between endothelm-1
spillover in the lungs and pulmonary vascular
resistance in patients with chronic heart faiレ
ure. J Am Coll Cardiol. 23: 1427-1433, 1994.
29) Tsutamoto T, Wada A, Maeda K, Hisanaga
T, Maeda Y, Fukai D, Ohnishi M, Sugimoto
Y, Kinoshita M: Attenuation of compensation
of endogenous cardiac natriuretic peptide
s stem in ch onic heart failure.Prognostic
role plasma br in natriuretic peptide concen-
tration in patients with chronic symptomatic
left ventricular dysfunction.: Circulation 96:
509-516, 1997.
30) Tsutamoto T, Hisanaga T, Atsuyuki W,
Keiko M, Masato 0, Daisuke F, Naoko M,
Masahide S, Masahiko K: Interleukin-6 Spil-
lover in the peripheral circulation inceases
with the severity of heart failure, and the high
plasma l vel of interleukin-6 is an important
prognostic predictor in patients with conges-
tive heart failure. J Am Coll Cardiol. 31: 1998
in press).
31) Yamauchi TK, Ihara Y, Ogata A, Yoshizaki
K, Azuma J, Kishimoto T: Hypoxic stress
induces cardiac myocyte-derived interleukin-
6. Circulation 91: 1520-1524, 1995.
32) Set  Y, Shan K, Bozkurt B, Oral H, Mann
DL: Basic Mechanism in Heart Failure: The
Cytokine Hyp thesis. Journal of Cardiac
F ilure 2: 243-250, 1996.
33) Xin X, Cai Y, Matsumoto K, Agui T:
Endothelin-induced interleukin-6 production
by rat aor ic endothelial cells. Endocrinology
-27-
久　永　智　子
-28-
136: 132-138, 1995.
